CMS Wants To Meet With Drug Firms Prior To Phase III Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks to offer input on trial design and endpoints to ensure they meet the outcome needs of purchasers. CMS also recommends that industry review coverage decisions for similar products.